S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
S&P 500   3,798.12 (+0.19%)
DOW   30,400.19 (+0.28%)
QQQ   283.45 (+0.47%)
AAPL   147.13 (+0.70%)
MSFT   250.40 (+0.61%)
META   140.04 (-0.17%)
GOOGL   101.82 (+0.18%)
AMZN   121.62 (+0.44%)
TSLA   241.62 (-3.14%)
NVDA   132.97 (+0.99%)
NIO   16.13 (-3.59%)
BABA   84.79 (+0.81%)
AMD   68.53 (+0.93%)
T   15.98 (-0.68%)
MU   55.03 (+1.98%)
CGC   3.05 (-2.87%)
F   12.53 (+1.38%)
GE   68.07 (+0.78%)
DIS   100.93 (-0.50%)
AMC   7.39 (-5.62%)
PYPL   94.45 (+1.79%)
PFE   44.26 (-0.45%)
NFLX   238.17 (-1.07%)
NASDAQ:BVXV

BiondVax Pharmaceuticals - BVXV News Today

$0.76
+0.06 (+8.63%)
(As of 10/4/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.70
$0.79
50-Day Range
$0.66
$1.26
52-Week Range
$0.65
$3.49
Volume
19,444 shs
Average Volume
140,192 shs
Market Capitalization
$8.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
Get BiondVax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.



BVXV Media Mentions By Week

BVXV Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BVXV
News Sentiment

0.85

0.79

Average
Medical
News Sentiment

BVXV News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BVXV Articles
This Week

3

1

BVXV Articles
Average Week

SourceHeadline
MarketBeat logoBiondVax Pharmaceuticals (NASDAQ:BVXV) Research Coverage Started at StockNews.com
americanbankingnews.com - October 4 at 2:28 AM
seekingalpha.com logoBiondVax gets Nasdaq non-compliance notice; files for stock offering
seekingalpha.com - September 30 at 1:00 PM
finance.yahoo.com logoBiondVax announces financial plans to support its ongoing NanoAb pipeline development
finance.yahoo.com - September 30 at 7:59 AM
MarketBeat logoZacks Small Cap Comments on BiondVax Pharmaceuticals Ltd.'s Q3 2022 Earnings (NASDAQ:BVXV)
americanbankingnews.com - September 28 at 1:04 AM
MarketBeat logoStockNews.com Initiates Coverage on BiondVax Pharmaceuticals (NASDAQ:BVXV)
americanbankingnews.com - September 27 at 2:40 AM
finance.yahoo.com logoBVXV: Results for Preclinical Inhalation Proof-of-Concept Study in COVID-19 Expected by End of This Year…
finance.yahoo.com - September 22 at 2:55 PM
benzinga.com logoBiondVax's Strategic Research Collaboration...
benzinga.com - September 21 at 11:45 PM
finance.yahoo.com logoBiondVax's Strategic Research Collaboration with Max Planck and UMG: Significant progress towards development of innovative nanosized antibodies (NanoAbs) for therapeutic indications in addition to COVID-19
finance.yahoo.com - September 20 at 5:32 PM
finance.yahoo.com logoBiondVax to Present at H.C. Wainwright 24th Annual Global Investment Conference
finance.yahoo.com - September 8 at 2:43 PM
msn.com logoBiondVax Pharmaceuticals: Q2 Earnings Insights
msn.com - August 25 at 12:29 PM
finance.yahoo.com logoBiondVax announces Second Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - August 25 at 12:29 PM
finance.yahoo.com logoBiondVax and European Investment Bank sign definitive amendment extending maturity of loan until December 2027 with additional terms in support of BiondVax's new strategy
finance.yahoo.com - August 10 at 1:32 PM
investing.com logoBVXV_t5 Historical Data
investing.com - August 2 at 10:31 PM
finance.yahoo.com logoBVXV: Significant Progress Made in NanoAb Program…
finance.yahoo.com - June 27 at 4:32 PM
finance.yahoo.com logoBiondVax receives supportive Scientific Advice from the Paul Ehrlich Institute (PEI) for COVID-19 NanoAb development plans including first-in-human Phase 1/2a safety and efficacy clinical trial
finance.yahoo.com - June 7 at 12:27 PM
seekingalpha.com logoBiondvax Pharmaceuticals reports Q1 results
seekingalpha.com - June 3 at 4:45 AM
investing.com logoBiondVax Pharma Reports Q1 Results
investing.com - June 1 at 8:52 AM
finance.yahoo.com logoBiondVax Announces First Quarter 2022 Financial Results and Provides Business Update
finance.yahoo.com - June 1 at 8:52 AM
finance.yahoo.com logoBiondVax to Present at H.C. Wainwright Global Investment Conference
finance.yahoo.com - May 19 at 6:11 PM
finance.yahoo.com logoBiondVax to Present at this week's Biomed Israel Conference
finance.yahoo.com - May 9 at 7:58 AM
finance.yahoo.com logoBVXV: Definitive Collaboration Agreement Signed to Develop Pipeline of NanoAb Therapies…
finance.yahoo.com - May 2 at 3:35 PM
finance.yahoo.com logoBiondVax to host a Hebrew-language analyst and investor webinar on April 6th
finance.yahoo.com - April 5 at 11:31 AM
finance.yahoo.com logoBiondVax to host analyst and investor webinar on April 4th
finance.yahoo.com - March 31 at 5:19 PM
seekingalpha.com logoBiondvax Pharmaceuticals GAAP EPS of -NIS0.07
seekingalpha.com - March 29 at 8:49 PM
finance.yahoo.com logoBiondVax Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
finance.yahoo.com - March 28 at 7:54 AM
benzinga.com logoHere's Why Biondvax Pharmaceuticals Shares Are Rising
benzinga.com - March 24 at 4:27 PM
finance.yahoo.com logoWhy Are BiondVax Pharma Shares Gaining Today?
finance.yahoo.com - March 24 at 4:27 PM
msn.com logoThe Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL
msn.com - March 24 at 11:26 AM
seekingalpha.com logoBiondVax stock soars 15% on research pact to develop nanosized antibody therapies
seekingalpha.com - March 24 at 11:26 AM
finance.yahoo.com logoBiondVax signs definitive collaboration agreement for the development of a pipeline of innovative nanosized antibody (NanoAb) therapies
finance.yahoo.com - March 24 at 11:26 AM
finance.yahoo.com logoEuropean Investment Bank Agrees in Principle to Extend the Maturity of its Loan until December 2027 with Additional Terms that Provide Continued Long-Term Support for BiondVax's New Strategy
finance.yahoo.com - March 14 at 2:21 PM
finance.yahoo.com logoBiondVax to Present at Aegis Virtual Conference
finance.yahoo.com - February 22 at 6:59 PM
finance.yahoo.com logoBiondVax to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 15 at 10:37 AM
finance.yahoo.com logoBVXV: Building a Pipeline of VHH Antibody Drug Candidates…
finance.yahoo.com - February 10 at 4:55 PM
nasdaq.com logoBiondVax Pharmaceuticals Ltd. American Depositary Shares (BVXV)
nasdaq.com - January 26 at 8:04 PM
finance.yahoo.com logoBiondVax to Present at Edison Group's Open House Conference
finance.yahoo.com - January 26 at 10:04 AM
finance.yahoo.com logoBiondVax to Present at H.C. Wainwright Bioconnect Virtual Conference
finance.yahoo.com - January 10 at 10:33 AM
finance.yahoo.com logoAegis Capital Corp. Acted as Sole Bookrunner on a $9.8 Million Underwritten Public Offering of ADSs for BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)
finance.yahoo.com - January 3 at 3:48 PM
finance.yahoo.com logoBiondVax Announces Successful Closing of $9.8 million Follow-on Underwritten Offering of ADSs Including Exercise of the Over-Allotment
finance.yahoo.com - December 29 at 9:03 PM
msn.com logoWhy BiondVax Shares Are Soaring Today
msn.com - December 22 at 6:49 PM
finance.yahoo.com logoBiondVax Shares More Than Double On Deal For Nanosized Covid-19 Antibody Therapy
finance.yahoo.com - December 22 at 6:49 PM
benzinga.com logoBiondVax signs definitive agreements for...
benzinga.com - December 22 at 1:49 PM
finance.yahoo.com logoBiondVax Shares Skyrocket After It Plans To In-License Nanosized COVID-19 Antibody
finance.yahoo.com - December 22 at 1:49 PM
marketwatch.com logoBiondVax Pharmaceuticals ADRs 56% Higher After Deal for Nanosized Covid-19 Antibody Therapies
marketwatch.com - December 22 at 8:48 AM
finance.yahoo.com logoBiondVax signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany
finance.yahoo.com - December 22 at 8:48 AM
finance.yahoo.com logoBiondVax announces Third Quarter 2021 Financial Results and Provides Business Update
finance.yahoo.com - November 30 at 7:51 AM
finance.yahoo.com logoBiondVax Announces Notice of Annual General Meeting of Shareholders and Provides a Business Update
finance.yahoo.com - November 24 at 5:54 PM
msn.com logoBRIEF-BiondVax Advances Its Growth Strategy Towards A New Pipeline Based On Innovative VHH Antibodies
msn.com - October 19 at 10:43 AM
finance.yahoo.com logoBiondVax advances its growth strategy towards a new pipeline based on innovative VHH antibodies
finance.yahoo.com - October 19 at 10:43 AM
nasdaq.com logoBiondVax Pharmaceuticals (NASDAQ:BVXV) Takes On Some Risk With Its Use Of Debt
nasdaq.com - September 4 at 5:34 PM
Get BiondVax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:BVXV) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.